IMMUNOSUPPRESSIVE TREATMENT IN CHILDREN WITH IgA NEPHROPATHY AND HENOCH-SCHÖNLEIN NEPHRITIS – NATIONAL STUDY

Małgorzata Mizerska-Wasiak[1], Agnieszka Turczyn[1], Agnieszka Such[1], Karolina Cichoń - Kawa[1],, Jadwiga Małdyk[2], Monika Miklaszewska[3], Jacek Pietrzyk[3], Agnieszka Rybi - Szumińska[4], Anna Wasilewska[4], Agnieszka Firszt - Adamczyk[5], Roman Stankiewicz[5], Beata Bieniaś[6], Maria Zajączkowska[6], Agnieszka Pukajło-Marczyk[7], Danuta Zwolińska[7], Katarzyna Siniewicz-Luzeńczyk[8], Marcin Tkaczyk[8], Katarzyna Gadomska - Prokop[9], Ryszard Grenda[9], Magdalena Drożynska - Duklas[10], Aleksandra Zurowska[10], Maria Szczepanska[11],Małgorzata Pańczyk - Tomaszewska[1]

[1]Medical University of Warsaw, Department of Pediatrics and Nephrology, Warsaw, POLAND, [2]Medical University of Warsaw, Department of Pathology, Warsaw, POLAND, [3]Jagiellonian University, Department of Pediatric Nephrology, Cracow, POLAND, [4]Medical University of Bialystok, Department of Pediatrics and Nephrology, Bialystok, POLAND, [5]Ludwik Rydygier Hospital, Department of Pediatrics and Nephrology, Torun, POLAND, [6]Medical University of Lublin, Department of Pediatric Nephrology, Lublin, POLAND, [7]Wroclaw Medical University, Department of Pediatric Nephrology, Wroclaw, POLAND, [8]Polish Mothers Memorial Hospital Research Institute, Department of Pediatrics, Immunology and Nephrology, Lodz, POLAND, [9]Children's Memorial Health Institute, Department of Nephrology, Kidney Transplantation and Hypertension, Warsaw, POLAND, [10]Medical University of Gdansk, Department of Pediatrics, Nephrology and Hypertension, Gdansk, POLAND, [11]SMDZ in Zabrze, Silesian Medical University, Department of Pediatrics, Katowice, POLAND.

INTRODUCTION

IgA nephropathy (IgAN) and Henoch Schoenlein nephritis (HSN) they are diseases with similar pathogenesis, IgA deposits in glomerules but different natural history.
The aim of this study is comparison of efficacy of **immunosuppressive treatment** based on clinical symptoms and Oxford classification in children with IgAN and HSN

METHODOLOGY

- **163 children** from group of 252 children from Polish National Registry in Children diagnosed with IgAN and HSN, recognized in renal biopsies
  - 90 HSN/73 IgAN
  - renal biopsies performed between 2000 – 2014
- **Oxford classification** (OC) was used to assess the severity of histopatological lesions
- **proteinuria** (mg/kg/day) and **GFR** (in Schwartz formula) at the onset of the disease (OOD) and at the end of treatment (EOT) were analyzed.
- **imunosuppressive drugs** (Prednisone, AZA, CYC, CsA) were used in treatment



RESULTS

- no significant differences in number of patients in the groups A, B, C between HSN and IgAN (*fig.1*).
- significantly higher proteinuria at OOD in C than B and A in HSN and IgAN
- prednisone alone and AZA+prednisone significantly decreased proteinuria in groups HSN and IgAN (*fig.2*).



Figure 1. Diferences in number of patients in A, B, C groups between HSN and IgAN.

- Cyclophosphamide or CsA + Prednisone decreased proteinuria significantly only in HSN but not in IgAN



Figure 2. Differences between proteinuria (mg/kg/d) at OOD and EOT in A, B, C groups, in HSN and IgAN.

Table 1. Results - summary.

		HSN			IgAN		
		OOD	EOT	p	OOD	EOT	p
PRED n=70	**Proteinuria (mg/kg/d)**	**21.5 (0-250)**	**0 (0-73)**	**<0.0001**	**14 (0-500)**	**0 (0-120)**	**0,051**
	MEST	**1.64±0.79**	-		**1.33±1,08**	-	NS
	GFR<90 (n)	**2**	**2**	**-**	**9 (12%)**	**5 (7%)**	NS
AZAPRED n=77	**Proteinuria (mg/kg/d)**	**42,5 (0-626)**	**0 (0-103)**	**<0.0001**	**18 (0-226)**	**0 (0-60)**	**<0.01**
	MEST	**1.74±0.83**	-	-	**1.83±1.09**	-	NS
	GFR<90 (n)	**0**	**1**	-	**10 (13%)**	**4 (6%)**	NS
CYC/CsA n=16	**Proteinuria (mg/kg/d)**	**120 (4.2-1140)**	**0 (0-92)**	**<0,001**	**41 (0-967)**	**25 (0-91)**	**NS**
	MEST	**2.16±1.02**	-	-	**1.83±1.09**	-	NS
	GFR<90 (n)	**2 (25%)**	**2 (25%)**	**NS**	**4 (50%)**	**2 (25%)**	NS

CONCLUSION

Immunosuppressive treatment has good effect in children with HSN and IgAN.

54 ERA
857--MP
Paediatric nephrology
Malgorzata Mizerska-Wasiak
DOI: 10.3252/pso.eu.54ERA.2017
ePosters supported by F. Hoffmann- La Roche Ltd.
PosterSessionOnline.com